Branded Legacy Inc. Unveils Cutting-Edge GMP Facility to Accelerate Life-Saving Inhaled Naloxone Development

Core Insights - BioLegacy Evaluative Group, Inc. has opened a new 22,000-square-foot Good Manufacturing Practice (GMP) facility in Vancouver, Canada, aimed at developing innovative, low-cost inhaled naloxone devices to address the opioid crisis [1][2] - The facility serves as a central hub for research, development, and production, leveraging partnerships with McMaster University and Stanford University to enhance the development of overdose-reversal solutions [2][6] - The CEO emphasized the facility's role in delivering affordable and accessible overdose-reversal solutions at scale, combining academic partnerships with advanced infrastructure [3][4] Facility Highlights - The new facility is dedicated to BioLegacy's inhaled naloxone program, improving the company's patented intranasal naloxone delivery device for better accessibility and dosing precision [5] - The infrastructure supports future expansion into nasal delivery of vaccines and other medications, creating opportunities for rapid pandemic response and improved access in underserved regions [5][6] - The facility is built to global pharmaceutical standards, featuring advanced ISO Class 7 & 8 cleanrooms and high-containment capabilities for safe handling of hazardous substances [7] Strategic Impact - The facility enhances BioLegacy's capabilities in developing safe and effective products to combat the opioid epidemic, with a focus on minimizing harm associated with hazardous materials [4][5] - The integration of in-house testing and regulatory expertise facilitates smoother product approvals, positioning the company for scalable, cost-effective solutions in high unmet need areas [7][8]